Hantavirus Global Situational Briefing - July 29, 2026

Executive read

The global hantavirus picture has no newly verified linked outbreak or official escalation in the current reporting set. Argentina's latest national bulletin remains above its historical calendar-year reference at 52 accumulated 2026 hantavirosis events versus a 2022-2025 median of 36, although the latest four-week comparison is below expected. Ukraine still has one publicly reported laboratory-confirmed HFRS case with an unresolved infection site. Venezuela's signal remains serious but lacks a public denominator. The M/V Hondius Andes-virus event remains closed at 13 cases and three deaths. 1 2 3 4

The main addition for clinical interpretation is a systematic review of haemostatic dysfunction in HFRS. Across 55 studies and 7,950 patients, thrombocytopenia was the most consistent abnormality. More severe platelet and bleeding patterns were reported with Hantaan, Dobrava and Seoul viruses than with Puumala, but heterogeneous study methods prevent a firm strain-specific prediction for an individual patient. 5

Signal table

Signal	Latest verified reading	Assessment at 08:00 on 29 July
Argentina	52 accumulated 2026 hantavirosis events versus a 2022-2025 median of 36; year-to-date above expected, latest four weeks below expected. 1	Elevated cumulative surveillance signal without a quantified new cluster.
Ukraine	One 53-year-old man from Stryi, Lviv region, with HFRS and hantavirus RNA detected by serum PCR. 2	Confirmed patient-level signal, not a documented cluster; infection site unresolved.
EU/EEA	ECDC's week 30 threat report, covering 18-24 July, contains no hantavirus, Andes-virus or Hondius item. 6	No new ECDC escalation in that bulletin. This does not establish zero European incidence.
Venezuela	Three confirmed deaths in Anzoátegui; two deaths involving health professionals in Barinas remain under investigation. 3	Serious but under-quantified. No case-fatality estimate is supportable.
M/V Hondius	WHO records 12 laboratory-confirmed and one probable case, with three deaths. All identified contacts completed follow-up without additional secondary cases. 4	Closed human-transmission event. The environmental source question remains separate.
Clinical evidence	A 55-study review covering 7,950 HFRS patients identifies thrombocytopenia as the most consistent haemostatic abnormality. 5	Useful for clinical surveillance, but not a diagnostic substitute for laboratory confirmation.

Argentina: cumulative excess, no recent acceleration

BEN 818 covers epidemiological week 28, 12-18 July. Its quick surveillance table lists 52 accumulated 2026 events, compared with a 2022-2025 median of 36. The same table marks the year-to-date comparison as above expected and the latest four-week comparison as below expected. A cumulative line can remain elevated while recent reporting falls below its short-term reference; these labels answer different questions. 1

The bulletin does not provide the fields needed to turn the national number into an outbreak description. It does not identify province, virus strain, exposure setting, deaths or diagnostic method for the 52 events. Those details should remain open rather than being inferred from the total.

The number also belongs to a calendar-year quick table, not the separate 2025-2026 seasonal series used in earlier Argentine disease-specific chapters. Combining the two would create a false denominator and could distort both incidence and fatality comparisons. The next informative release would be a disease-specific or provincial breakdown that explains the composition of the national total.

Europe: one confirmed case, several unresolved variables

The Lviv regional health authority reported a 53-year-old man from Stryi with HFRS. Hantavirus RNA was detected in serum by PCR, while testing for Leptospira interrogans was negative. The report says illness began on 12 July with fever, chills, headache, nausea, appetite loss and calf pain. It does not identify a hantavirus species or genotype. 2

The epidemiological investigation recorded travel on Croatia's Makarska Riviera from 1-7 July and travel through mountainous areas of western Ukraine on 11 July. The patient reported no contact with mouse-like rodents, nests or excreta, and the report does not establish whether infection occurred in Croatia, Ukraine or another setting. Swimming in the Adriatic and washing hands in a local river are recorded exposures, not confirmed transmission routes. Local preventive and epidemiological measures are under way.

ECDC's week 30 Communicable Disease Threats Report covers 18-24 July and lists other infectious-disease topics, but no hantavirus, Andes-virus or Hondius section. That is a bounded finding about one regional bulletin. It does not override national notification systems or show that Europe has no additional infections. 6

The next European facts that would change the assessment are a second linked case, a defined exposure setting, species or genotype information, or a clinical outcome that changes the severity picture. None is established in the current record.

Americas: Venezuela remains a denominator problem

The latest public account from Venezuela reports three confirmed hantavirus deaths in Anzoátegui, including cases reported from Boca del Pao. It also reports two deaths involving health professionals in Barinas that remain under investigation. The available account does not provide a confirmed or suspected case denominator, onset-date series, municipality-level case list, strain, diagnostic method or rodent findings. 3The figures therefore cannot support a case-fatality estimate, an outbreak-size estimate or a conclusion about person-to-person spread. The Barinas deaths should remain outside the confirmed hantavirus count until testing or an official case definition places them there. The immediate surveillance need is a ministry or state-level line list with case classification, dates, geography, laboratory method and exposure history.

Chile is not assigned a current count in this briefing because the latest indexed Ministry of Health hantavirus bulletin is not available as a readable primary document in the current source set. Search snippets are not used as a substitute for a national case report.

Asia-Pacific and the closed ship event

No new Asia-Pacific human case count is added here. Singapore's public communication continues to frame the cruise-linked issue as contained and relevant to international travel rather than as a local case series. Health New Zealand's official page continues to report no identified human or animal hantavirus cases in Aotearoa New Zealand, no known exposed person and low local risk. 7 8

WHO's final event notice records 13 ship-linked cases, including 12 laboratory-confirmed Andes-virus infections and one probable case, with three deaths. All identified contacts completed the 42-day follow-up period. WHO reports 317 high-risk contacts completed quarantine or monitoring and 336 low-risk contacts completed self-monitoring, with no additional secondary cases detected. It assesses the outbreak as no longer posing a public-health risk and expects no further related transmission. 4

The environmental source investigation remains a separate scientific question. A rodent or environmental result would refine attribution of the ship-linked event, but would not by itself reopen the completed contact-follow-up assessment.

Research watch: what the HFRS review adds

The systematic review examined observational studies and case series covering 55 studies and 7,950 patients. Meta-analysis was not feasible because study designs and outcome reporting were too heterogeneous. The most consistent finding was thrombocytopenia, with more pronounced abnormalities reported in Hantaan, Dobrava and Seoul infections than in Puumala infections. Mildly prolonged activated partial thromboplastin time and elevated D-dimer were reported inconsistently. 5

For surveillance and care, the value is practical but limited. HFRS is a clinical syndrome, not a virus species. A public notice that confirms HFRS does not justify assigning Hantaan, Dobrava, Seoul or Puumala virus, and the review does not provide a basis for predicting an individual patient's outcome from the syndrome label alone. Platelet and coagulation abnormalities should be interpreted with the clinical course and laboratory confirmation, not used as a shortcut for strain attribution.

The review also exposes a research gap. Variable study quality and incomplete reporting make it difficult to compare bleeding outcomes across regions and strains. Standardised prospective collection of platelet counts, coagulation markers, renal injury, bleeding events and clinical outcomes would make future outbreak reports more useful for both triage and epidemiological comparison.

Watchpoints for the next briefing

Argentina: a disease-specific bulletin or provincial breakdown that explains the 52-event calendar-year total.
Ukraine: clinical outcome, exposure location, species or genotype, and any linked case.
Venezuela: a confirmed and suspected denominator, diagnostic details, onset dates, municipality-level geography and rodent findings.
Europe and Asia-Pacific: a national notification or authority alert that changes the current post-response posture.
M/V Hondius: ecological or genomic results identifying a source. This would refine attribution, not by itself reopen the transmission event.
HFRS clinical reporting: prospective data that connect haemostatic abnormalities with strain, renal injury, bleeding and outcome using consistent definitions.

At 08:00 on 29 July 2026, the global assessment is stable but clinically better defined. Argentina's cumulative calendar-year signal remains above its reference without a recent four-week excess; Ukraine has one confirmed HFRS case with unresolved exposure; Venezuela remains serious but incompletely quantified; and the Hondius human-transmission event remains closed. The new review supports closer attention to haemostatic abnormalities in HFRS, while leaving strain attribution and individual prognosis to direct laboratory and clinical evidence.